

Audit of Antiplatelet Therapy Post MI and for the Therapy of Acute Coronary Syndromes

References:

NICE CG 172 Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease

NICE TA 236 Ticagrelor for the therapy of acute coronary syndromes

NICE TA 317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

NICE TA 420 Ticagrelor for preventing atherothrombotic events after myocardial infarction

Question Number	Details	Example	Number of Patients
1	How Many Patients are currently prescribed:		
1a	Aspirin + Clopidogrel	10	
1b	Aspirin + Ticagrelor	25	
1c	Aspirin + Prasugrel	5	
1d	Total Number of Patients	40	
2a	How many of the patients identified in question 1d have been prescribed dual antiplatelet therapy for greater than 13 months?	20	
2b	How many of the patients identified in question 2a prescribed dual antiplatelet therapy for greater than 13 months have a valid indication for continuing therapy beyond 13 months documented within the patients notes or discharge letter?	12	
3a	How many of the patients identified in question 1d have been prescribed dual antiplatelet therapy for less than 13 months?	20	
3b	How many of the patients identified in question 3a prescribed dual antiplatelet therapy for less than 13 months have a stop date on the prescription?	15	
3c	How many of the patients identified in question 3a prescribed dual antiplatelet therapy for less than 13 months have a valid indication for continuing therapy beyond 12 months documented within the patients notes or discharge letter?	2	

Calculations

		Example	Number of Patients
A	% of patients prescribed dual therapy who have received greater than 13 months supply without a valid indication = 2a minus 2b divided by 1d	20%	
B	% of patients prescribed dual therapy for less than 13 months supply with a stop date on the prescription (excluding patients with a valid indication to continue therapy) = 3b divided by 3a minus 3c	83%	

Audit Standards

A - 0% patients should receive dual therapy for greater than 13 months without a valid indication

B - 100% patients should have a stop date on the prescription unless there is a valid indication to continue therapy.